These 4 charts show the scale of Novo Nordisk's woes
š”Analysis & Context
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market. Monitor developments in These for further updates.
š Quick Summary
Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the
Original Source:
Read full article at sourceHelp us improve this article. Share your feedback and suggestions.




